help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on May 1, 2008
Endocrinology, doi:10.1210/en.2007-1566
A more recent version of this article appeared on August 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
149/8/4218    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Debaveye, Y.
Right arrow Articles by Van den Berghe, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Debaveye, Y.
Right arrow Articles by Van den Berghe, G.

Submitted on November 13, 2007
Accepted on April 16, 2008

Effects of Substitution and High Dose Thyroid Hormone Therapy on Deiodination, Sulfoconjugation and Tissue Thyroid Hormone Levels in Prolonged Critically Ill Rabbits

Yves Debaveye, Björn Ellger, Liese Mebis, Theo J. Visser, Veerle M. Darras, and Greet Van den Berghe*

Department of Intensive Care Medicine, Laboratory of Comparative Endocrinology, Catholic University of Leuven, B-3000 Leuven, Belgium; Department of Internal Medicine, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands; Department of Anesthesiology and Intensive Care Medicine, University Hospital of Muenster, D-48149 Muenster, Germany

* To whom correspondence should be addressed. E-mail: greet.vandenberghe{at}med.kuleuven.be.

To delineate the metabolic fate of thyroid hormone in prolonged critically ill rabbits, we investigated the impact of two dose regimes of thyroid hormone on plasma T2 and T4S, deiodinase type 1 (D1) and D3 activity and tissue iodothyronine levels in liver and kidney, as compared with saline and TRH. D2 expressing tissues were ignored. The regimens comprised either substitution dose or a 3- to 5- fold higher dose of T4 and T3, either alone or combined, targeted to achieve plasma thyroid hormone levels obtained by TRH.

Compared with healthy animals, saline-treated ill rabbits revealed lower plasma T3 (P=0.006), hepatic T3 (P=0.02) and hepatic D1 activity (P=0.01). Substitution-dosed thyroid hormone therapy did not affect these changes except a further decline in plasma (P=0.0006) and tissue T4 (P=0.04). High-dosed thyroid hormone therapy elevated plasma and tissue iodothyronine levels and hepatic D1 activity, as did TRH. Changes in iodothyronine tissue levels mimicked changes in plasma. Tissue T3 and tissue T3/rT3 ratio correlated with deiodinase activities. Neither substitution nor high-dosed treatment altered plasma T2. Plasma T4S was only increased by T4 in high dose.

We conclude that in prolonged critically ill rabbits, low plasma T3 levels were associated with low liver and kidney T3 levels. Restoration of plasma and liver and kidney tissue iodothyronine levels was not achieved by thyroid hormone in substitution dose, but instead required several fold this dose. This indicates thyroid hormone hypermetabolisation, which in this model of critical illness is not entirely explained by deiodination nor by sulfoconjugation.


Key words: Thyroid hormone • Critical illness • Thyroxine Sulfate • Di-iodothyronine • Deiodinase • Thyrotropin releasing hormone







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society